Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW: LTI-03 in idiopathic pulmonary fibrosis
2025-520715-13-00Phase 2Authorised
- Sponsor
- Rein Therapeutics
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing LTI-03 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Apr 2026; status: authorised.
02
Drugs
LTI-03
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-520715-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520715-13-00.